European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI)
A long-running European medical journal that publishes new research on radioactive scans and radioactive treatments.
Overview
EJNMMI traces back to the European Journal of Nuclear Medicine (EJNM), founded in 1975 and based in Hannover, Germany; it was renamed European Journal of Nuclear Medicine and Molecular Imaging and, according to Springer, was the official journal of the European Association of Nuclear Medicine (EANM) until December 2024. The journal covers clinical and scientific work in functional, metabolic and molecular investigation of disease: diagnostic and therapeutic radiopharmaceuticals, image-guided therapy, physics, dosimetry, radiation biology, radiochemistry and radiopharmacy, plus reviews, short communications and letters (it does not publish case reports).
In February and July 2025, EANM announced the end of its publishing partnership with Springer Nature and the EJNMMI journal family, and launched two of its own open-access journals with Elsevier — The EANM Journal and EANM Innovation — as the society's new flagship venues. EJNMMI itself continues to publish with Springer Nature independently of that society affiliation; papers citing pre-2025 EANM-endorsed guidelines will generally reference EJNMMI, while post-2025 EANM guidance is increasingly appearing in the new EANM journals instead.
Because of that transition, records in this graph should check the publication year of any paper before assuming EJNMMI carries current EANM endorsement.
A Stanford nuclear medicine professor who led the division for a decade and has published widely on new PET tracers, from FAPI scans of fibrosis-related proteins to whole-body PET scanners that image the entire body at once.
An Australian medical physicist who helped prove that SPECT scans, not just PET scans, can measure exact amounts of radioactivity in the body, which underpins accurate dosing of radioactive cancer treatments.
An Italian-trained nuclear medicine doctor who helped develop the lutetium-177 dotatate treatment for neuroendocrine tumours and now leads targeted radionuclide therapy at Memorial Sloan Kettering in New York.
A German medical physicist who has led the physics section of Würzburg's nuclear medicine department for three decades and helped set the international standards used to calculate radiation doses from radioactive cancer treatments.
Peter Bartenstein is a nuclear medicine head whose department is a leading European PSMA theranostics centre.
One of the pioneers of peptide receptor radionuclide therapy for neuroendocrine tumours, now practising at the Curanosticum theranostics centre in Wiesbaden.
Leads the nuclear medicine group behind the first human TROP2 PET imaging, aiming to pick patients for TROP2 ADCs with a scan.
An Italian nuclear medicine professor who built one of Europe's busiest PET centres in Bologna and co-writes the international guidelines that tell doctors when and how to use PSMA PET scans in prostate cancer.
A German nuclear medicine doctor at Essen who helped design a scoring system, RECIP, for reading follow-up PSMA scans in prostate cancer patients on lutetium therapy, and who co-writes the field's international imaging guidelines.
Similar pages
not linked directly; found by shared links- JournalClinical Nuclear Medicine
Shares the tags journal, nuclear medicine.
- JournalJournal of Nuclear Cardiology
Shares the tags journal, nuclear medicine.
- PersonPaola Anna Erba
Shares European Association of Nuclear Medicine and the tag nuclear medicine.